Evidence map›Paper›PMID 40014293›Full record

ReviewDiabetes therapy : research, treatment and education of diabetes and related disorders2025

In-Hospital Management of Hyperglycemia: The Role of Insulin Degludec.

Subhash Kumar Wangnoo, Manash P Baruah, Sailesh Lodha, Debmalya Sanyal, Ramesh Goyal, Basavaraj G Sooragonda, Sruti Chandrasekaran, G Vijay Kumar

Registry-linked trialAbstract readReview
In one paragraph

Review in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07626775 (To Assess the Prevalence, Management Practices, and Clinical Outcomes Associated With Hyperglycemia Among Hospitalized Patients, With a Particular Focus on the Interplay Between Metabolic Biomarkers, Nutritional Status, and Body Composition), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07626775 completednot on this map

To Assess the Prevalence, Management Practices, and Clinical Outcomes Associated With Hyperglycemia Among Hospitalized Patients, With a Particular Focus on the Interplay Between Metabolic Biomarkers, Nutritional Status, and Body Composition

Typeobservational_patient_registrySponsorMedanta, The Medicity, IndiaRan2023 to 2026Enrolled362ConditionsDiabete Mellitus, Diabete Type 2, Hyperglycaemia (Diabetic)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Subhash Kumar WangnooDiabetes and Endocrinology (ACODE), Apollo Centre for Obesity, New Delhi, India.
Manash P BaruahApollo Excelcare Hospital, Guwahati, Assam, India.
Sailesh LodhaEndocrinology, Eternal Hospital, Jaipur, Rajasthan, India.
Debmalya SanyalDepartment of Endocrinology, KPC Medical College, Kolkata, West Bengal, India.
Ramesh GoyalDepartment of Diabetology and Endocrinology, Apollo Hospital International Limited, Gandhinagar, Gujarat, India.
Basavaraj G SooragondaDepartment of Endocrinology, Diabetes and Metabolism, Narayana Health, Bengaluru, Karnataka, India.
Sruti ChandrasekaranDepartment of Endocrinology, Rela Hospital, Chennai, Tamil Nadu, India.
G Vijay KumarApollo Speciality Hospital, Diabetes Medicare Centre, Chennai, India. diabetesgoodlife@yahoo.co.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHyperglycemia is a common and challenging condition in hospitalized patients both with and without a history of diabetes. Managing hyperglycemia effectively is critical in reducing complications, mortality, and the length of hospital stays. Insulin degludec (IDeg), an ultralong-acting basal insulin, has a well-established efficacy and safety profile in terms of managing hyperglycemia in outpatients; it has demonstrated benefits in clinical practice across various patient populations. This review aims to assess the evidence on its clinical suitability, as well as efficacy and safety, for managing hyperglycemia across different inpatient populations. The review specifically focuses on outcomes such as glycemic control, glycemic variability, safety (particularly hypoglycemia risk), dosing flexibility, ease of titration, and use in special populations.

methodsA comprehensive literature search was conducted using PubMed to identify studies published between 2014 and 2024. Eligible studies included randomized controlled trials, real-world evidence, and case series that examined the use of IDeg for hyperglycemia management in hospitalized patients.

resultsThe reviewed studies consistently demonstrated that IDeg provides stable and predictable glycemic control with low glycemic variability. The ultralong duration of action, ability to be titrated daily, and flexibility in dosing make IDeg suitable for noncritical care settings with difficult-to-maintain rigid insulin schedules. Furthermore, the risk of hypoglycemia, particularly nocturnal hypoglycemia, is low with IDeg. These attributes are beneficial across diverse inpatient populations. Practical advantages, such as ease of administration with a specialized delivery device, further support its use in hospital settings.

conclusionsUnique pharmacokinetic and pharmacodynamic properties of IDeg, reduced glycemic variability, low hypoglycemia risk, ease of daily titration, and dosing flexibility make it appropriate for managing hyperglycemia in hospitalized patients.

Indexed as

Basal insulinGlycemic variabilityIn-hospital managementInsulin dosing flexibilityOn-critical care settings

Identifiers

PMID40014293
PMCPMC11925827

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.